



Aldeyra Therapeutics to Participate in the Jefferies and A.G.P./Alliance Global Partners Virtual Investor Conferences

November 13, 2020

LEXINGTON, Mass.--(BUSINESS WIRE)--Nov. 13, 2020-- [Aldeyra Therapeutics, Inc.](https://ir.aldeyra.com) (Nasdaq: ALDX) (Aldeyra) today announced that the company's senior management will participate in the following virtual investor conferences:

- **Jefferies Virtual London Healthcare Conference:** Aldeyra President and CEO Todd C. Brady, M.D., Ph.D., is scheduled to participate in a fireside chat at 1:10 p.m. ET on Wednesday, November 18, 2020. The fireside chat will be broadcast live and archived for 90 days on the company's website at <https://ir.aldeyra.com> on the "Events & Presentations" page. In addition, company executives are scheduled to host virtual one-on-one meetings with institutional investors.
- **A.G.P./Alliance Global Partners Virtual Healthcare Symposium:** Aldeyra executives are scheduled to host virtual one-on-one meetings with institutional investors on November 19, 2020.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF- κ B, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in development for COVID-19 and ovarian cancer. For more information, visit <https://www.aldeyra.com/> and follow us on [LinkedIn](#), [Facebook](#), and [Twitter](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20201113005085/en/): <https://www.businesswire.com/news/home/20201113005085/en/>

Corporate Contact:

David McMullin
Aldeyra Therapeutics, Inc.
Tel: 781-761-4904 ext. 218
dmcnullin@aldeyra.com

Investor & Media Contact:

Scott Solomon
Sharon Merrill Associates, Inc.
Tel: 617-542-5300
ALDX@investorrelations.com

Source: Aldeyra Therapeutics, Inc.